Differential expression of acidic proteins with progression in the MCF10 model of human breast disease

International Journal of Oncology

Volumn 31, Issue 4, 2007, Pages 941-949

  Buchanan, Nathan S ^a   Zhao, Jia ^a   Zhu, Kan ^c   Patwa, Tasneem H ^a   Miller, Fred R ^d   Lubman, David M ^b  

^a UNIVERSITY OF MICHIGAN   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^c NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^d WAYNE STATE UNIVERSITY   (United States)

Author keywords

Breast cancer; Mass spectrometry; Proteomics; Two dimensional liquid separations

Indexed keywords

PROTEOME; TUMOR MARKER; TUMOR PROTEIN;

ARTICLE; BREAST TUMOR; DISEASE COURSE; ELECTROSPRAY MASS SPECTROMETRY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; ISOELECTRIC FOCUSING; MASS SPECTROMETRY; METABOLISM; PEPTIDE MAPPING; TWO DIMENSIONAL GEL ELECTROPHORESIS;

BREAST NEOPLASMS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DISEASE PROGRESSION; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; HUMANS; ISOELECTRIC FOCUSING; NEOPLASM PROTEINS; PEPTIDE MAPPING; PROTEOME; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; TUMOR MARKERS, BIOLOGICAL;

EID: 35848934803     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.31.4.941     Document Type: Article

References (42)

1. Miller FR: Xenograft models of premalignant breast disease. J Mam Gland Biol 5: 379-381, 2000.
2. Miller FR, Soule HD, Tait L, Pauley RJ, Wolman SR, Dawson PJ and Heppner GH: Xenograft model of progressive human proliferative breast disease. J Natl Cancer Inst 85: 1725-1732, 1993. (Pubitemid 23320842)
3. Santner SJ, Dawson PJ, Tait L, Soule HD, Eliason J, Mohamed AN, Wolman SR, Heppner GH and Miller FR: Malignant MCF10CA1 cell lines derived from premalignant human breast epithelial MCF10AT cells. Breast Cancer Res Treat 65: 101-110, 2001.
4. Yan F, Subramanian B, Nakeff A, Barder TJ, Parus SJ and Lubman DM: A comparison of drug-treated and untreated HCT-116 human colon adenocarcinoma cells using a 2-D liquid separation mapping method based upon chromatofocusing pI fractionation. Anal Chem 75: 2299-2308, 2003.
5. Klose J and Kobalz U: Two-dimensional electrophoresis of proteins: an updated protocol and implications for a functional analysis of the genome. Electrophoresis 16: 1034-1059, 1995.
6. Klose J: Protein mapping by combined isoelectric focusing and electrophoresis of mouse tissues. A novel approach to testing for induced point mutations in mammals. Humangenetik 26: 231-243, 1975.
7. Sluyterman LAA and Elgersma O: Chromatofocusing-isoelectric-focusing on ion-exchange columns. 1. General Principles. J Chromatogr 150: 17-30, 1978.
8. Kachman MT, Wang HX, Schwartz DR, Cho KR and Lubman DM: A 2-D liquid separation/mass mapping method for interlysate comparison of ovarian cancers. Anal Chem 74: 1779-1791, 2002.
9. Hamler RL, Zhu K, Buchanan NS, Kreunin P, Kachman MT, Miller FR and Lubman DM: A two-dimensional liquid-phase separation method coupled with mass spectromic studies of breast cancer and biomarker identification. Proteomics 4: 562-577, 2004. (Pubitemid 38339137)
10. Buchanan NS, Hamler RL, Leopold PE, Miller FR and Lubman DM: Mass mapping of cancer cell lysates using two-dimensional liquid separations, electrospray-time of flight-mass spectrometry, and automated data processing. Electrophoresis 26: 248-256, 2005.
11. Williams TL, Leopold P and Musser S: Automated postprocessing of electrospray LC/MS data for profiling protein expression in bacteria. Anal Chem 74: 5807-5813, 2002.
12. Baker PR and Clauser KR. http://prospector.ucsf.edu.
13. Boeckmann B, Bairoch A, Apweiler R, Blatter MC, Estreicher A, Gasteiger E, Martin MJ, Michoud K, O'Donovan C, Phan I, Pilbout S and Schneider M: The SWISS-PROT protein knowledge base and its supplement TrEMBL in 2003. Nucleic Acids Res 31: 365-370, 2003.
14. Brotherick L, Robson CN, Browell DA, Shenfine J, White MD, Cunliffe WJ, Shenton BK, Egan M, Webb LA, Lunt LG, Young JR and Higgs MJ: Cytokeratin expression in breast cancer: phenotypic changes associated with disease progression. Cytometry 32: 301-308, 1998.
15. El-Rehim DMA, Pinder SE, Paish CE, Bell J, Blamey R, Robertson JFR, Nicholson RI and Ellis IO: Expression and co-expression of the members of the epidermal growth factor receptor (EGFR) family in invasive breast carcinoma. J Pathol 203: 661-671, 2003.
16. Yashioka K, Foletta V, Bernard O and Itoh K: A role for LIM kinase in cancer invasion. Proc Natl Acad Sci USA 100: 7247-7252, 2003. (Pubitemid 36706424)
17. Helmbrecht K, Zeise E and Rensing L: Chaperones in cell cycle regulation and mitogenic signal transduction: a review. Cell Prolif 33: 341-365, 2000.
18. Fernandez PM, Tabbara SO, Jacobs LK, Manning FCR, Tsangaris TN, Schwartz AM, Kennedy KA and Patierno SR: Overexpression of the glucose-related stress gene GRP78 in malignant but not benign human breast lesions. Breast Cancer Res Treat 59: 15-26, 2000.
19. Wulfkuhle JD, Sgroi DC, Krutzsch H, McLean K, McGarvey K, Knowlton M, Chen S, Shu HJ, Sahin A, Kurek R, Wallwiener D, Merino MJ, Petricoin EF, Zhao YM and Steeg PS: Proteomics of human breast ductal carcinoma in situ. Cancer Res 62: 6740-6749, 2002.
20. Lim SO, Park SG, Yoo J, Park YM, Kim H, Jang K, Cho JW, Yoo BC, Jung GH and Park CK: Expression of heat shock proteins (HSP27, HSP60, HSP70, HSP90, GRP78, GRP94) in hepatitis B virus-related hepatocellular carcinomas and dysplastic nodules. World J Gastroenterol 11: 2072-2079, 2005.
21. Wadhwa R, Takano S, Kaur K, Deocaris CC, Pereira-Smith OM, Reddell RR and Kaul SC: Upregulation of mortalin/mthsp70/GRP75 contributes to human carcinogenesis. Int J Cancer 118: 2973-2980, 2006.
22. Wadhwa R, Takano S, Taira K and Kaul SC: Reduction in mortalin level by its antisense expression causes senescence-like growth arrest in human immortalized cells. J Gene Med 6: 439-444, 2004. (Pubitemid 40228060)
23. Celli CM and Jaismal AK: Role of GRP58 in mitomycin C-induced DNA cross-linking. Cancer Res 63: 6016-6025, 2003.
24. Janssen AML, Bosman CB, Kruidenier L, Griffioen G, Lamers CBHW, van Krieken JHJM, van de Velde CJH and Verspaget HW: Superoxide dismutases in the human colorectal cancer sequence. J Cancer Res Clin Oncol 125: 327-335, 1999.
25. Noh DY, Ahn SJ, Lee RA, Kim SW, Park IA and Chae HZ: Overexpression of peroxiredoxin in human breast cancer. Anti-cancer Res 21: 2085-2090, 2001.
26. Warburg O: Metabolism of Tumors. Arnold Constable, London, 1930.
27. Cuezva JM, Krajewska M, De Heredia ML, Krajewski S, Santamaria G, Kim H, Zapata JM, Marusawa H, Chamorro M and Redd JC: The bioenergetic signature of cancer: a marker of tumor progression. Cancer Res 62: 6674-6681, 2002.
28. Dang CV and Semenza GL: Oncogenic alterations of metabolism. Trends Biochem Sci 24: 68-72, 1999.
29. Zhao J, Zhu K, Miller FR and Lubman DM: Proteomic analysis of estrogen response of premalignant human breast cells using a 2-D liquid separation/mass mapping technique. Proteomics 6: 3847-3861, 2006. (Pubitemid 44065162)
30. Shekhar MPV, Nangia-Makker P, Wolman SR, Tait L, Heppner GH and Visscher DW: Direct action of estrogen on sequence of progression of human preneoplastic breast disease. Am J Pathol 152: 1129-1132, 1998.
31. Yang E, Kim H, Lee J, Shin JS, Yoon H, Kim SJ and Choi IH: Overexpression of LIM kinase 1 renders resistance to apoptosis in PC12 cells by inhibition of caspase activation. Cell Mol Neurobiol 24: 181-192, 2004.
32. Felty Q, Xiong WC, Sun DM, Sarkar S, Singh KP, Parkash J and Roy D: Estrogen-induced mitochondrial reactive oxygen species as signal transducing messages. Biochemistry 44: 6900-6909, 2005.
33. Felty Q and Roy D: Mitochondrial signals to nucleus regulate estrogen-induced cell growth. Med Hypotheses 64: 133-141, 2005.
34. Shekhar PVM, Chen ML, Werdell J, Heppner GH, Miller FR and Christman JK: Transcriptional activation of functional endogenous estrogen receptor gene expression in MCF10AT cells: a model for early breast cancer. Int J Oncol 13: 907-915, 1998.
35. Paz A, Haklai R, Elad-Sfadia G, Ballan E and Kloog Y: Galectin-1 binds oncogenic Hras to mediate ras membrane anchorage and cell transformation. Oncogene 20: 7486-7493, 2001. (Pubitemid 33086908)
36. Elad-Sfadia G, Haklai R, Ballan E, Gabins HJ and Kloog Y: Galectin-1 augments ras activation and diverts ras signals to Raf-1 at the expense of phosphoinositide 3-kinase. J Biol Chem 277: 37169-37175, 2002.
37. Wadhwa R, Yaguci T, Hasan MK, Taira K and Kaul SC: Mortalin-MPD (mevalonate pyrophosphate decarboxylase) interactions and their role in control of cellular proliferation. Biochem Biophys Res Commun 302: 735-742, 2003.
38. Kothari S, Cizeau J, McMillan-Ward E, Israels SJ, Bailes M, Ens K, Kirshenbaum LA and Gibson SB: BNIP3 plays a role in hypoxic cell death in human epithelial cells that is inhibited by growth factors EGF and IGF. Oncogene 22: 4734-4744, 2003. (Pubitemid 36976448)
39. Powis G, Mustacich D and Coon A: The role of redox protein thioredoxin in cell growth and cancer. Free Radic Biol Med 29: 312-322, 2000.
40. Liu F, Rong Y-P, Zeng L-C, Zhang X and Han Z-G: Isolation and characterization of a novel human thioredoxin-like gene hTLP19 encoding a secretory protein. Gene 315: 71-78, 2003.
41. McCarthy MM, Sznol M, DiVito KA, Camp RL, Rimm DL and Kluger HM: Evaluating expression and prognostic value of TRAIL-R1 and TRAIL-R2 in breast cancer. Clin Cancer Res 11: 5188-5194, 2005.
42. Wang TTY and Jeng J: Coordinated regulation of two TRAIL-R2/KILLER/DR5 mRNA isoforms by DNA damaging agents, serum and 17β-estradiol in human breast cancer cells. Breast Cancer Res Treat 61: 87-96, 2000.